Citius Pharmaceuticals, Inc. (CTXR) Form 10-Q — Aug 14, 2026
Citius Pharmaceuticals' fiscal Q3 2026 10-Q carries explicit going-concern language: with $17.0 million in cash at June 30, 2026 and negative working capital of roughly $8.3 million, management estimates available cash funds operations only through November 2026, and Citius Oncology has retained Jefferies LLC to evaluate strategic alternatives. The quarter delivered the company's first meaningful product revenue from the LYMPHIR launch — $1.49 million for the three months and $7.11 million for the nine months ended June 30, 2026, versus zero a year earlier — but the nine-month net loss widened to $49.4 million from $31.0 million, with $23.0 million of operating cash consumed.
Key figures
- Eps
- -0.34 (fiscal Q3); -1.64 (nine months)
- Revenue
- 1493788
- Total Debt
- 10000000
- Revenue Yoy
- N/A — prior-year quarter had $0 revenue (LYMPHIR commercial sales began December 2025)
- Total Assets
- 142255198
- Cash Position
- 17007523
- Shares Outstanding
- 27452570
- Cash Runway
- operations funded through November 2026
- Shares Growth
- 18,067,744 at 9/30/25 to 27,452,570 at 8/13/26
- Gross Margin Q3
- approximately 67%
- Payer Coverage
- 135 health plans representing 80% of covered lives
- Vials Ordered Q3
- 926 vs. 708 prior quarter (+31%)
- Nine Month Revenue
- 7105197
- Term Loan Maturity
- November 1, 2029
- Reverse Split Ratio
- 1-for-25 (effective November 25, 2024)
- Term Loan Funded To Date
- 10000000
- Term Loan Interest Rate
- greater of prime + 6% or 12.75%
- Term Loan Facility Total
- 25000000
- Negative Working Capital
- approximately $8.3 million
- Warrants Outstanding CTOR
- 53947473
- Warrants Outstanding CTXR
- 23247210
- Institutions Ordering LYMPHIR
- 44
- Dr Reddys Milestone Payable Remaining
- 15650000
Price after filing
Close on the filing date to close N calendar days later (from $0.76). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.